- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Immune System Diseases1000+
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Immune System Diseases1000+
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- PD-L1 positive
- HER2 positive
- PR positive
- PR negative
- ER negative
- PD-L1 negative
- EGFR positive
- BRAF positive
- KRAS positive
- p16 positive
- EGFR negative
- BRCA1 positive
- BRCA2 positive
- HLA-A positive
- ALK negative
- CD20 positive
- IDH positive
- ALK positive
- CD19 positive
- MET positive
- HLA positive
- BRAF negative
- MYC positive
- HLA negative
- ROS1 positive
- p16 negative
- ROS1 negative
- HPV positive
- TP53 positive
- MSI-H positive
- RB1 positive
- RET positive
- HLA-A negative
- IDH negative
- MET negative
- PALB2 positive
- dMMR positive
- HR positive
- RB1 negative
- NRAS positive
- PIK3CA positive
- BRCA positive
- BCL2 positive
- CCND1 positive
- FLT3 positive
- HPV negative
- NF1 positive
- RAS positive
- MSS positive
- KRAS negative
- ATM positive
- BCL6 positive
- CD30 positive
- MMR positive
- NTRK positive
- BCR-ABL1 positive
- PTEN positive
- Philadelphia chromosome positive
- RET negative
- BRCA1 negative
- CD5 positive
- HbSS positive
- MGMT negative
- MSH2 positive
- RAS negative
- TP53 negative
- BRCA2 negative
- KIT positive
- MLH1 positive
- MSH6 positive
- PMS2 positive
- p53 positive
- ANA positive
- MMR negative
- MSI negative
- PD-1 positive
- ctDNA positive
- dMMR negative
- ARID1A positive
- BRIP1 positive
- CDK12 positive
- CHEK2 positive
- MGMT positive
- NRAS negative
- RAD51 positive
- anti-dsDNA positive
- CD22 positive
- FGFR2 positive
- FLT3 negative
- MSI positive
- MSI-H negative
- NTRK negative
- RAD51C positive
- FANCA positive
- HBV DNA negative
- HBsAg positive
- L858R positive
- NF2 positive
- NTRK1 positive
- PD-1 negative
- RAD51D positive
- SMN1 positive
- bcr-abl positive
- del(17p) positive
- t(11;14) positive
- BRCA negative
- CD19 negative
- CFTR positive
- CLDN18.2 positive
- Ex19del positive
- FGFR3 positive
- HPV16 positive
- HR negative
- HRD positive
- JAK2 positive
- Ki-67 positive
- MSS negative
- pMMR positive
- t(9;22) positive
- ABCA4 positive
- BARD1 positive
- CD123 positive
- CD4 positive
- COL7A1 positive
- Complex karyotype positive
- HBB positive
- HBV DNA positive
- HBsAg negative
- HRAS positive
- NPM1 positive
- PTEN negative
- RF positive
- SMARCB1 positive
- TERT positive
- AR positive
- ASXL1 positive
- BAP1 positive
- CD20 negative
- CD3 positive
- CD33 positive
- CD4 count positive
- CDK4 positive
- CHEK1 positive
- FANCL positive
- FGFR positive
- HbSC positive
- MDM2 positive
- MSH6 negative
- NBN positive
- PDGFRA positive
- PH positive
- PMS2 negative
- Philadelphia chromosome negative
- RAF positive
- RB positive
- RUNX1 positive
- SMARCB1 negative
- SMN2 positive
- TMB positive
- TROP2 positive
- TTR positive
- t(11;14)(q13;q32) positive
- AKT1 positive
- APC positive
- APOL1 positive
- CCND1 negative
- CCND2 positive
- CCND3 positive
- CD23 positive
- CD70 positive
- CD8 positive
- CDK6 positive
- CTNNB1 positive
- DLL3 positive
- DMD positive
- EBV positive
- EPCAM positive
- EZH2 positive
- FMR1 positive
- FRα positive
- GLA positive
- GRN positive
- H3 K27M positive
- HBcAb positive
- IA-2A positive
- ICA positive
- IGHV positive
- KMT2A positive
- MECP2 positive
- MLH1 negative
- MRE11 positive
- MSH2 negative
- MTAP positive
- MYC negative
- RAD54L positive
- SF3B1 positive
- SMARCA4 positive
- SRSF2 positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- 2 Episodes of Recurrent Clostridium Difficile Infection
- 2 or More Previous Chemotherapies
- 68Ga-DOTATATE PET/CT Scan
- >= 2 Bone Metastases (Untreated Lesion)
- ALK TKI Therapy
- ANC >= 1,500/mcL
- AST/ALT =< 3 x ULN
- ATG
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
10334 trials
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to see if bitopertin is effective and safe in treating EPP or XLP in participants aged 12 and above. It will investigate whether bitopertin can increase pain
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to compare the effects of different types of fluids given during surgery on acid-base balance and electrolytes in young patients. Patients will be randomly assigned to receive either normal saline or hypertonic saline
Efficacy & Safety Awards
No Placebo-Only Group
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial aims to test a combination of interventions, including improving sleep, cognitive exercises, and extended pain relief after heart surgery to reduce confusion, agitation, and decline in cognitive function. These interventions are based
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial will test a new long-acting HIV treatment for people who still have detectable virus levels despite taking oral medication. The study will look at how well the treatment works, how safe it is
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether giving azithromycin along with standard antibiotics to 8,000 women having a cesarean delivery can help reduce infections after childbirth. The study will compare the rates of
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial will randomly assign participants to receive either Luminopia dichoptic treatment, Vivid Vision dichoptic treatment, or continued optical correction alone. Participants will be assessed at 9 and 18 weeks
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares two types of radiation therapy for treating cancer that has spread to the brain. One type, called fractionated stereotactic radiosurgery (FSRS), delivers a high dose of radiation over
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
Summary"This trial aims to see if barzolvolimab is effective, safe, and well-tolerated in adults with Chronic Spontaneous Urticaria who have not responded well to common
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial is comparing the effects of combining immunotherapy (pembrolizumab) with chemotherapy (doxorubicin) versus using chemotherapy alone to treat patients with undifferentiated pleomorphic sar
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Get notified when new Lazy Eye trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to compare two treatments for children aged 4 to 7 with lazy eye. One treatment involves watching special movies with a headset for 1 hour per day, 6 days a week
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test if plozasiran injection is safe and effective in adults with high triglyceride levels. Participants will receive either plozasiran or a placebo every 3 months for a
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
Summary"This trial will test a new injection called plozasiran in adults with very high levels of triglycerides. Participants will receive either plozasiran or a placebo every 3 months for a
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test the safety and effectiveness of plozasiran injection in adults with severe high levels of triglycerides. Participants will receive either plozasiran or a placebo every 3 months
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial compares two drugs, rituximab and mosunetuzumab, in treating patients with low tumor burden follicular lymphoma. Rituximab targets a protein found on B
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing the effectiveness of ZILRETTA in reducing pain in people with glenohumeral osteoarthritis when compared to a placebo. The secondary objectives include comparing the pain
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug called pelacarsen to see if it is effective and safe for Black/African American and Hispanic individuals with heart disease and high levels of Lp(a). Participants
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to compare the overall survival of patients with certain types of advanced soft tissue sarcomas who have already tried 2 standard treatments, including one with anthracycline, with a new
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial will investigate the impact of a single dose of SRP-9003 on beta-sarcoglycan gene expression in individuals with limb-girdle muscular dystrophy type 2E/R
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Idiopathic Pulmonary Fibrosis trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial is for people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis who have completed treatment with a medicine called BI 1015550 in a previous study. The goal is to see how
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if adding a monoclonal antibody called dinutuximab to standard treatments like chemotherapy and stem cell transplantation can help treat children with a type of cancer called high risk neuroblast
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
1
2
3
…50